Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

Ariel Global Composite fell -3.51% gross of fees (-3.65% net of fees) in the quarter, trailing the -0.99% return posted by ...

SK Group Chairman Chey Tae-won has said the chips-to-battery conglomerate could consider making more investments in the ...